FFPE Scrolls

Download a copy of our ONCOREF™ information (PDF) from below:

Please type the letters below

OncoREF

The ONCOREF™ series of molecular reference standards is generated using footprint-free genome editing with the CRISPR/Cas9 platform.  Because these samples are footprint free – meaning that no selection markers are employed in the engineering process – you are able to focus on the mutations in your samples, rather than having to worry about the presence of residual recombinase sites or genomic footprints from other gene editing technologies, such as rAAV.  

Reference Standard Features:

•  Most comprehensive MAPK mutation panel on the market
•  Footprint-free genome editing
•  Isogenically-paired mutant and wild-type cell lines
•  Homozygous knock-in of the desired mutation
•  Reference cell lines are expanded from single-cells, ensuring maximum homogeneity
•  Available in multiple formats, including slides, scrolls, and full FFPE blocks

ONCOREF™ FFPE Blocks: Inquire for full FFPE block pricing

Need FFPE standards using your own cell lines?  Take advantage of our Custom FFPE Cell Line Services, or contact us for more details.

About the MAPK Pathway


The MAPK signaling pathway encompasses a series of signal transduction events that flow from the engagement of EGFR at the outer cell membrane, through KRAS, BRAF, MEK, and ERK.  MAPK signaling ultimately results in transcriptional activation of key genes that promote cellular proliferation, survival, differentiation, motility, and angiogenesis[1].  As such, the MAPK pathway is one of the most frequently activated pathways in cancer[2], and several drugs have pharmacogenomics profiles that depend upon the MAPK mutational status[3]. 

 

 

 

 

 

To learn more about our FFPE Reference Standards and other diagnostic products, WATCH our WEBINAR!

Technical Details

Consistent Source of Biorelevant Specimens

- FFPE bio-mimetic specimens using FFPE cell line blocks

TECHNICAL-ONCOREF-MAPK-FFPE-cellline-blocks

Support Materials

ONCOREF™ Reference Standards: Application of CRISPR/Cas9 to the Generation of Isogenic Cell Lines and Reference Materials (October 2016)

2016-Oncoref-webinar

CRISPR/Cas9 is rapidly enabling the development of new tools for enhancing our understanding oncogenic mutations in cancer. In order to aid in advancing cancer diagnosis and treatment, Applied StemCell has recently engineered a series of 40 isogenic cell lines that feature diverse mutations in the MAPK pathway. These mutant lines are available as isogenic pairs for applications in lead compound discovery, or as FFPE and nucleic acid reference materials for assay development. This webinar will focus on ASC’s efforts in developing these research tools, as well as applications of the materials for the advancement of cancer research.

Highlights of this talk:

  • Overview of molecular reference materials 
  • Workflow and QC for ONCOREF™ cell line generation
  • Advantages of CRISPR-engineered molecular reference standards
  • Applications of reference materials in assay development
  • Q & A
FAQ

1. What is the thickness of the FFPE scrolls?

Answer: We prepare 20µm sections using 6.5mm diamater FFPE cell blocks.

2. How are your cell lines generated? 

Answer: ASC uses CRISPR/Cas9 technology to enable precision genome editing in its MAPK mutation panel series.  This technology allows for footprint-free gene modification, meaning that you don’t have to worry about the presence of selection markers or other genomic footprints during the development of your assay technologies.

3. How do you validate mutational status in your cell lines? 

Answer: All of our MAPK mutation panel cell lines are expanded from single clones.  This ensures maximum homogeneity of the genetic profile.  After clonal expansion, we confirm the mutational status of the cell line using Sanger sequencing.

4. Do you offer mixtures of mutant and wild-type DNA? 

Answer: We are currently working with collaborators to develop these products.  Please inquire for additional information.

References
  • Akinleye A, Furqan M, Mukhi N, Ravella P, Liu D (2013) MEK and the inhibitors: from bench to bedside. J. Hematol. Oncol. 6, 1–11
  • Santarpia L, Lippman SM, El-Naggar AK (2012) Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy, Expert Opin. Ther. Targets 16, 103–119
  • Relling MV, Evans WE (2015) Pharmacogenomics in the clinic, Nature 526, 343–350
Ordering

Items 1-10 of 53

Page
per page